Diagnosing The Causes of Poor Pharmaceutical Systems Performance Marc J. Roberts Professor of Political Economy and Health Policy Harvard School of Public.

Slides:



Advertisements
Similar presentations
New Challenges in M&E Lets go. Scaling Up Monitoring & Evaluation Strategic Information PROGRAM GUIDANCE RESULT NEEDS OPPORTUNITIES Resources New directions.
Advertisements

Introduction to the Flagship Framework
Toebes, May 2010 Human rights, health sector commercialisation and corruption Dr Brigit Toebes, The University of Aberdeen School of Law
IGCSE®/O Level Economics
CUTS INTERNATIONAL Assessing Policy based Competition Impediments in Pharmaceutical and Agriculture Product Marketing Sector in India 1 Swati Thapar, Research.
PROFAMILIA The CATALYST Consortium PROFAMILIA/COLOMBIA AND THE HEALTH SECTOR REFORM IN COLOMBIA María Isabel Plata PROFAMILIA - COLOMBIA JULY 16, 2003.
Health System Strengthening for Greater Health Impact Dan Kraushaar Management Sciences for Health We all say we do it and do it well, but what is it?
Monitoring and Evaluation Frameworks Kyiv, Ukraine May 23, 2006 MEASURE Evaluation.
Planning and organization of health survey Ashry Gad Mohamed Professor of epidemiology.
ECON 850 Health Economics Gilleskie Lecture 1: Introduction What is economics? What is health economics?
Monitoring and Evaluation Frameworks   What is an M&E Framework?   Why do we use M&E Frameworks?   How do we develop M&E Frameworks? MEASURE Evaluation.
Supply Chains Management for Pharmacy
Access to HIV/AIDS, Tuberculosis and Malaria Medicines. WHO/UNICEF Technical Briefing Seminar on Essential Medicines Policies. Geneva, 18 – 22 September.
HEALTH CARE MARKET Dr. Nabilla Abdul Mohsein Al-Sadat.
Generating evidence for change: Implementing the post-ICIUM research agenda Dennis Ross-Degnan, ScD Harvard Medical School and Harvard Pilgrim Health Care.
1.Define marketing and describe its contributions. 2. Differentiate among the concepts of needs, wants, and demands. 3. Define the concept of exchange.
Georgian Health Care 2020 Washington DC, February 1-2, 2010
3rd Baltic Conference on Medicines Economic Evaluation, Reimbursement and Rational Use of Pharmaceuticals Pricing and Reimbursement of Pharmaceuticals.
National Medicine Policy
Politics, Values and Interests: the Debate over Supplemental Insurance in Israel Prof. Revital Gross The Smokler Center for Health Policy Research, Myers-JDC-Brookdale.
CH 1. Factors accounting for the growth of importance in the health sector  Global health and longevity gains  Expansion of health sector throughout.
Utilization of TB control services in Kenya Analysis of wealth inequalities Christy Hanson, PhD, MPH World Health Organization Stop TB Department.
Ajaz S. Hussain, Ph.D. Deputy Director Office of Pharmaceutical Science, CDER, FDA ACPS Subcommittee on Manufacturing Science: Identification and Prioritization.
Identifying Problems—Outcomes for Judging System Performance Marc J Roberts Professor of Political Economy and Health Policy Harvard School of Public Health.
Medicines Transparency Alliance01/10/2015 Availability of Medicines Anita Wagner Harvard Medical School & WHO Collaborating Center in Pharmaceutical Policy.
Cambodia1. 2 Cambodia Assessment Ung Phirun Chroeng Sokhan.
3 August 2004 Public Health Practice III: FINANCING PUBLIC HEALTH REFORM Thomas E. Novotny MD MPH University of California San Francisco Institute for.
ASSESSMENT OF AVAILABILITY, PRICE AND AFFORDABILITY OF MEDICINES FOR CHILDREN IN GHANA Authors: Gyansa-Lutterodt M. 1,Andrews Annan E. 2, Koduah A. 1,
CHAPTER 6 The Economic Role of the State PUBLIC SECTOR ECONOMICS: The Role of Government in the American Economy Randall Holcombe.
Margarit MELIKYAN Drug Utilization Research Group PO, Armenia, National Institute of Health Access to and Use of Medicines by Households in Armenia: Impact.
Stop the Stock-outs! Civil Society approaches to monitoring PSM for essential medicines Christa Cepuch BSc Phm Health Action International (HAI) Africa.
Macroeconomics 2.6 Supply-side policies (market-based)
Engaging Communities and the Workforce through Co-production Gerry Power National Lead – Coproduction and Community Capacity Building Shifting the Focus.
Impact of a NGO-supported supervisory programme on the quality of care in private shops in rural E.Nepal Kathleen Holloway Bharat Raj Gautam Britain Nepal.
What are coalitions? A coalition is a formal arrangement for cooperation and collaboration between groups or sectors of the community, in which each group.
Medicines Transparency Alliance31/10/ MeTA Zambia – Pricing Goodwell Lungu MeTA Secretary General.
FIFTH MEETING OF HEALTH TEAM IHP+ COUNTRIES 2 – 5 December 2014, Siem Reap, Cambodia SESSION 7c) Managing Purchasing and Stock in Guinea-Bissau Current.
Getting Health Reform Right From Diagnosis to Health Sector Reform Shahram Yazdani.
Market and Command Economies
April Harding Bali Hyatt Hotel, Sanur, Bali June 2010.
Pharmacists Perceptions of the Development of Herbal Medicines in Iran
WHO-Technical Briefing Seminar | October-November 2012 Dr Cécile Macé 1 |1 | Good Governance for Medicines Programme Dr Cécile Macé EMP/MPC.
Language Barriers in Health Care Spanish speaking patients (w/ limited English proficiency) & English speaking medical personnel.
Health and Ageing Risk and Uncertainty in National Network for Integrated Continuous Care Joint World Conference on Social Work and Social Development:Action.
Health Facility Surveys: An Introduction by Magnus Lindelow and Adam Wagstaff December 12, 2001 Revised April 25, 2006 Based on Policy Research Working.
The effectiveness of the Health Card as an instrument to ensure access to medical care for the poor during the crisis Fadia Saadah Menno Pradhan Robert.
Agriculture Today Unit 1: Agribusiness in Today’s Agriculture Industry Lesson: AT1.
Chapter 2: The Role of Economics
Farid Abolhassani Markets and Efficiency 10. Learning Objectives After working through this chapter, you will be able to: List and describe the assumptions.
MONITORING THE PHARMACEUTICAL SECTOR IN A DEVELOPING COUNTRY - THE GHANA EXAMPLE Gyansa-Lutterodt M. 1,7, Andrews E 2, Arhinful D 3,7, Addo-Atuah J 4,7,
State Regulation in the Natural Monopoly Sphere Agency of the Republic of Kazakhstan on Regulation of Natural Monopolies ALMATY – 2006.
MeTA Phase I: Where are we? MeTA18/06/ MeTA2 The MeTA Phase I Proposal Purpose To pilot a new multi-stakeholder approach towards increasing transparency.
REDESIGNING ORGANIZATION & MANAGEMENT SYSTEMS (IHSDNs Attributes # 7, 8, 9,10, 11, 12, 13) (IHSDNs Attributes # 7, 8, 9,10, 11, 12, 13) July , 2015.
Preventing Corruption & Bribery - Perspectives from the Regulators-
Health Technology Assessment
Sustainable Community Based Rehabilitation at local and national levels Presented by Professor Gwynnyth Llewellyn (University of Sydney) and Darryl Barrett.
Marketing.
International Conference on Improving Use of Medicines
Financing Heath Care in Low Income Coutnries
C h a p t e r 2 EFFICIENCY, MARKETS, AND GOVERNMENTS
I3U Commitment 27 “A – Public Sector Innovation Scoreboard B – Research Programme on Public Sector and Social Innovation“ Venue: Vienna, I3U Project Meeting.
Health Care Financing: User Fees
EFFICIENCY, MARKETS, AND GOVERNMENTS
HSA 510Competitive Success/tutorialrank.com
HSA 510 Education for Service-- tutorialrank.com.
Market and Command Economies
Economic systems Analysis Who makes the economic decisions?
Prize Concept Review Framework
Here’s how you can make an impact:
Here’s how you can make an impact:
Presentation transcript:

Diagnosing The Causes of Poor Pharmaceutical Systems Performance Marc J. Roberts Professor of Political Economy and Health Policy Harvard School of Public Health Pharmaceutical Workshop Nairobi 12 April,

2 Clarifying Concepts: Efficiency Technical efficiency: Producing outputs at minimum costs – drugs purchased and distributed at minimum cost (HOW outputs are produced) Allocative efficiency: Producing the right outputs to achieve our goals – buying the right drugs to provide cost effective care for the population (WHAT outputs are produced)

3 Clarifying Concepts: Access The ability of patients to use services That they want to use That experts believe they should use

Why Is Access Important? Influences utilization, health status and satisfaction Price barriers (formal and informal) undermine risk protection Political leaders often advocate for access as an end –we see it as a means 4

Monitoring Access Physical availability is not the same as effective availability Low use can reflect demand factors as well as supply conditions To evaluating effective access requires a population survey of utilization and its determinants 5

Finding the Causes of Poor Sector Pharmaceutical Performance : Drawing A Diagnostic Tree Work “backward” from performance problems to causes and the causes of causes Ask “Why?” five times Seek to identify those causes that could be altered by policy changes 6

What You Will Discover on Such a Journey Most performance problems have more than one cause Many causes have more than one effect Improving performance will often require more than one action 7

Example of a Diagnostic Tree Poor Purchasing Lack of ACTs in Logistical Failures Public Clinics Theft Lack of Gov’t Funds High Levels of Malaria In Rural Areas Lack of Retail High Prices for ACTs Competition in Private Sector No Retail Price Regulation

Points About a “Diagnostic Tree” For each cause there can be more than one further cause Causes can impact more than one other cause The result may be messy—the arrows can cross 9

Guidance on the Process Work backwards Do not jump to conclusions Be scientific Respect data Be specific Look for causes you can fix 10